Psychedelic trials use randomized, placebo-controlled clinical trials to show efficacy on primary end points.

The new executive order uses the Veterans Health System to anchor psychedelic therapy treatment and research.

Using “Right to Try” may define how early access can occur before FDA approval.

The April 18th White House executive order on psychedelics is best understood not as a legalization measure, but a policy shift accelerating treatment development. The Administration framed it explicitly as a mental health initiative—“Removing barriers to psychedelic drugs"—for serious mental illnesses like PTSD, depression, and addiction

The Executive Office (EO) explicitly frames psychedelics as a response to treatment-resistant mental illness in veterans—PTSD, suicide, depression, and substance use disorders. Military veterans are the primary clinical population around which these federal psychedelic initiatives are organized. The Veterans Health Administration (VHA) is a proving ground—a structured, federally-integrated system where psychedelic therapies can be studied, validated, and potentially deployed under tight controls.

The EO directs coordination between the Department of Veterans Affairs and agencies such as the NIH and the FDA to expand clinical trials and data sharing. The EO encourages veteran participation in clinical trials or expanded access programs, positioning the VA as a controlled- access environment.

Veterans with refractory PTSD, suicidal thoughts, substance abuse, or depression—difficult populations to treat with conventional pharmacotherapy—are prioritized.

The President’s order directs federal agencies to facilitate clinical trial participation, expand access pathways such as Right-to-Try mechanisms, and prioritize regulatory review. This creates real momentum—compressing development timelines, signaling to regulators, researchers, and investors that psychedelics are a federal priority. However, it does not alter statutory requirements for approval: the FDA still requires substantial evidence of safety and efficacy.

The immediate regulatory impact of the EO is already visible. Three companies—Compass Pathways (COMP360 psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD)—received FDA Commissioner’s National Priority Vouchers following the EO. In parallel, the FDA permitted clinical development of DemeRx’s DMX-1001 (oral noribogaine hydrochloride) for treating alcohol use disorder, marking the first U.S. clinical pathway for an ibogaine-derived therapy.

Comments From Experts

At the White House signing and in subsequent comments, Nora Volkow, MD,........

© Psychology Today